Grayhawk Capital is a Manager of Translational Venture Partners, the manger of Translational Accelerator, LLC (TRAC), a $20 million fund investing in promising life science companies. Through TRAC we look to invest in companies working in the oncology and neuroscience fields. TRAC focuses specifically on companies that are in the process of moving scientific discoveries from the lab to the clinic, the “translational stage.” Our primary goal is to work with promising companies that are driven by talented doctors or researchers. By sifting through promising research we are able to advance opportunities that can make a difference in people’s lives and speed the therapy’s progress toward regulatory approval.